Abbott Laboratories (ABT) announced yesterday, positive results from ABSORB II non-inferiority trials. These trials compared the safety and efficacy of Abbott's "dissolving Absorb heart device" with the company's leading Xience class of drug-eluting stents (DES). ABSORB trials were conducted on 501 patients in Europe, and their results were announced at the 26th Transcatheter Cardiovascular Therapeutics symposium yesterday.
Abbott Proves Its New Stent Technology As Non-Inferior To Its Own "Xience"
Bidness etc. - 15 Sep 2014 13:30
Abbott Laboratories (ABT) announced yesterday, positive results from ABSORB II non-inferiority trials. These trials compared the safety and efficacy of Abbott's "dissolving Absorb heart device" with the company's leading Xience class of drug-eluting stents (DES). ABSORB trials were conducted on 501 patients in Europe, and their results were announced at the 26th Transcatheter Cardiovascular Therapeutics symposium yesterday.
Share this Article
Recommended